Novavax | NVAX - Selling And Administration Expenses


Novavax reported $25.53M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Adma Biologics USD 26.74M 5K Jun/2026
Agenus USD 6.21M 4.34M Mar/2026
AstraZeneca USD 4.07B 1.73B Sep/2026
BioCryst Pharmaceuticals USD 63.98M 31.8M Jun/2026
Cassava Sciences USD 3.37M 521K Jun/2026
Geron USD 35.7M 3.16M Sep/2026
GlaxoSmithKline GBP 2.16B 39M Sep/2026
MannKind USD 61.41M 3.11M Sep/2026
Merck USD 2.86B 25M Sep/2026
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Moderna USD 282M 66M Sep/2026
Novartis USD 3.08B 58M Sep/2026
Novavax USD 25.53M 1.34M Dec/2025
Pfizer USD 3.28B 132M Sep/2026
Sanofi EUR 2.31B 325M Sep/2026
Sarepta Therapeutics USD 118.61M 11.01M Sep/2026
TG Therapeutics USD 62.32M 10.82M Jun/2026